Vosoritide

Regenerative repair

Tissue repair, structural remodeling, or healing support

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Regenerative peptide / tissue compound
Primary mechanism: Tissue repair, extracellular matrix, collagen, angiogenesis, or cell migration pathways
Primary market use: Regenerative repair

Pharmacology

Molecular weight (Da): 4162.78
Oral bioavailability: Route-dependent / verify
Half-life: ~5–60 min parent peptide; analogs may be longer
Route tags: SubQ; Injectable; route-dependent
Evidence level: MCE product listing / research chemical signal
Clinical status: Research chemical/reference listing
Value-for-money score: 9 / 10

Reported protocol signal

No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Stackability

Place in regenerative repair/tissue remodeling comparison clusters.

Notes

Vosoritide (BMN 111) is a modified recombinant CNP (C-type natriuretic peptide) analogue, binds to NPR-B ( natriuretic peptide receptor type B ) and reduces the activity of FGFR3 ( fibroblast growth factor receptor 3 ). Vosoritide can be used in achondroplasia and dwarfism research.

Sources

https://www.medchemexpress.com/vosoritide-acetate.html